Cargando…
Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS
The COVID-19 pandemic caused by the novel SARS-CoV-2 is more contagious than other coronaviruses and has higher rates of mortality than influenza. As no vaccine or drugs are currently approved to specifically treat COVID-19, identification of effective therapeutics is crucial to treat the afflicted...
Autores principales: | O’Donovan, Sinead M, Eby, Hunter, Henkel, Nicholas D, Creeden, Justin, Imami, Ali, Asah, Sophie, Zhang, Xiaolu, Wu, Xiaojun, Alnafisah, Rawan, Taylor, R. Travis, Reigle, James, Thorman, Alexander, Shamsaei, Behrouz, Meller, Jarek, McCullumsmith, Robert E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336712/ https://www.ncbi.nlm.nih.gov/pubmed/32702077 http://dx.doi.org/10.21203/rs.3.rs-25643/v1 |
Ejemplares similares
-
Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach
por: O’Donovan, Sinead M., et al.
Publicado: (2021) -
Connecting omics signatures and revealing biological mechanisms with iLINCS
por: Pilarczyk, Marcin, et al.
Publicado: (2022) -
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection
por: Creeden, Justin Fortune, et al.
Publicado: (2021) -
Altered purinergic receptor expression in the frontal cortex in schizophrenia
por: Alnafisah, Rawan, et al.
Publicado: (2022) -
Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
por: Imami, Ali S., et al.
Publicado: (2021)